Oncolytics Biotech (ONCY) director buys 30,000 shares in open market

Rhea-AI Filing Summary

Oncolytics Biotech Inc. director Wayne Pisano reported an open-market purchase of 30,000 common shares of ONCY on February 12, 2026. The shares were bought at a weighted average price of $0.8446 per share, in multiple trades ranging from $0.83 to $0.85.

Following this transaction, Pisano directly holds 492,414 common shares of Oncolytics Biotech Inc. The filing notes that detailed trade-by-trade pricing information is available upon request for investors or regulators who want to review each individual purchase within the reported price range.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pisano Wayne

(Last) (First) (Middle)

C/O ONCOLYTICS BIOTECH INC.

4350 EXECUTIVE DRIVE, SUITE 325

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ONCOLYTICS BIOTECH INC [ ONCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/12/2026		P		30,000	A	$0.8446(1)	492,414	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.83 to $0.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

	/s/ Kirk Look, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ONCY director Wayne Pisano report?

Director Wayne Pisano reported buying 30,000 Oncolytics Biotech Inc. common shares. The open-market purchase occurred on February 12, 2026, and increased his directly held position to 492,414 shares, according to the Form 4 insider trading report.

At what price did ONCY director Wayne Pisano buy his shares?

Wayne Pisano bought 30,000 ONCY common shares at a weighted average price of $0.8446. The filing explains that individual trades were executed between $0.83 and $0.85 per share, with detailed breakdowns available upon request from the company or regulators.

How many ONCY shares does Wayne Pisano own after this transaction?

After the reported purchase, Wayne Pisano directly owns 492,414 Oncolytics Biotech Inc. common shares. This total reflects the addition of 30,000 shares bought in the February 12, 2026 open-market transaction disclosed in the Form 4 filing.

Was the ONCY insider transaction a buy or a sell?

The ONCY insider transaction was a buy. Director Wayne Pisano executed an open-market purchase of 30,000 common shares, coded as a “P” transaction, which denotes a purchase in the Form 4 reporting framework for insider trades.

What does the weighted average price mean in the ONCY Form 4?

The weighted average price of $0.8446 reflects multiple trades between $0.83 and $0.85. Instead of listing each execution, the Form 4 aggregates them, and notes that detailed trade-level pricing is available to the issuer, shareholders, or SEC staff upon request.